Anzeige
Mehr »
Freitag, 05.06.2026 - Börsentäglich über 12.000 News
UraniumX startet heiß ersehntes Bohrprogramm mitten im neuen Uran-Superzyklus
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D3KD | ISIN: US50535E1082 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
PROSOMNUS INC Chart 1 Jahr

Aktueller Chart PROSOMNUS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
PROSOMNUS INC-Investoren interessieren sich auch für diese Wertpapiere
BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 GuidanceLOUISVILLE, Ky., May 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services...
► Artikel lesen
BrightSpring mischt einen Milliardenmarkt aufAuf den ersten Blick ist das Geschäft von BrightSpring margenschwach und wenig attraktiv. Doch gerade das eröffnet enorme Chancen für Skalierung und Konsolidierung Den vollständigen Artikel lesen ...
► Artikel lesen
BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to SevitaLOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and...
► Artikel lesen
Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business...
► Artikel lesen
Veru Inc.: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027- --Company to host conference call and...
► Artikel lesen
Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue GuidanceMENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Provides Guidance for 2026MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 ResultsMENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
► Artikel lesen